1. Introduction
===============

*Pasteurella multocida* is a Gram negative opportunistic pathogenic bacterium living in the nasal, pharyngeal space of animals. Human infections occur usually by scratches and bites of domesticated animals (e.g., mainly cats and dogs). In addition, contact with salvia is sufficient for colonization of bacteria \[[@B1-toxins-02-00205]\]. *P. multocida* is of particular importance in livestock management, especially of pigs. The infection of swine with *P. multocida* leads under special conditions to a atrophic rhinitis that was first described by Franque in 1830 \[[@B2-toxins-02-00205]\]. A main symptom in pigs is the loss of nasal turbinate bones leading to a twisted or shortened snout. The causative agent of atrophic rhinitis is a protein toxin produced by *P. multocida* (*Pasteurella multocida* toxin, PMT) \[[@B3-toxins-02-00205],[@B4-toxins-02-00205]\].

2. Signal Transduction and Molecular Mechanism of PMT
=====================================================

PMT stimulates a variety of signal transduction pathways ([Figure 1](#toxins-02-00205-f001){ref-type="fig"}). Phospholipase C (PLC) β, which is activated by Gα~q~, is stimulated to catalyze inositol trisphosphate production and Ca^2+^ mobilization. In addition, the small GTPase RhoA is activated leading to stress fiber formation. Moreover, PMT is a strong mitogen in various cell lines. These effects are mainly due to the activation of heterotrimeric G proteins of the Gα~q~ and Gα~12/13~ family. Furthermore, PMT activates Gα~i~ thereby inhibiting adenylyl cyclase. Toxin-induced activation of heterotrimeric G proteins (e.g., G~i~) releases Gβγ, which stimulates signaling pathways.

![Scheme of PMT-activated heterotrimeric G proteins and subsequent signaling pathways. PMT activates Gα~i~ to inhibit adenylyl cyclase (AC). PMT-induced activation of Gα~13~ and Gα~q~ stimulates Rho guanine nucleotide exchange factors (RhoGEF) leading to the activation of the low molecular mass GTPase RhoA. Moreover, activation of Gα~q~ leads to stimulation of the Jak-STAT (Janus kinase, signal transducer and activator of transcription) pathway and the canonical Gα~q~ effector phospholipase Cβ (PLCβ). By activation of the Gα-subunit, Gβγ is released from the heterotrimeric complex and mediates signaling via βγ-specific effectors, e.g., phosphoinositide-3-kinase (PI3K)γ.](toxins-02-00205-g001){#toxins-02-00205-f001}

PMT was found to be an extremely potent mitogen for several cell types. Concentrations as low as 1 to 2 pM stimulate DNA synthesis \[[@B5-toxins-02-00205]\]. However, the toxin induces proliferation of osteoblasts even though one of the PMT-induced symptoms is the atrophy of nasal turbinate bones. The underlying signaling pathways that govern PMT-induced proliferation are largely unknown. In HEK293 cells, PMT transactivates the epidermal growth factor (EGF) receptor in a Gα~q~-dependent manner. However, in cardiomyocytes the stimulation of the MAP kinase pathway occurs in an EGF receptor-independent manner \[[@B6-toxins-02-00205],[@B7-toxins-02-00205]\]. Therefore, the PMT-induced pathways to enhance proliferation seem to be cell type specific.

PMT enhances inositol trisphosphate production by activation of PLCβ, which in turn is stimulated by α-subunits of the Gα~q/11~ family \[[@B5-toxins-02-00205],[@B8-toxins-02-00205]\]. Studies with Gα~q~ and Gα~11~ gene deleted mouse embryonic fibroblasts (MEF) showed that PMT activates PLCβ only via Gα~q~ but not via the closely related Gα~11~\[[@B9-toxins-02-00205]\]. This observation is noteworthy given that Gα~q~ and Gα~11~ are 89% identical at the amino acid sequence level and Gα~q~-coupled receptors are generally found to activate Gα~11~ too. PMT distinguishes between both G proteins on the basis of the helical domain, which is inserted into the highly conserved GTPase domain. Replacement of helix αB of Gα~11~ by the Gα~q~ helix enabled the toxin to activate the mutant Gα~11~ protein. However, introduction of helix αB of Gα~11~ into Gα~q~ leads to a chimera, which is not activated by PMT \[[@B10-toxins-02-00205]\].

Besides the stimulation of the prototypical Gα~q~ effector PLCβ, the toxin stimulates the Jak-STAT (Janus kinase, signal transducer and activator of transcription) pathway in a Gα~q~-dependent manner \[[@B11-toxins-02-00205]\]. PMT activates STAT1, 3 and 5 leading to altered gene expression, e.g. up-regulation of cancer-associated cyclooxygenase (COX)-2 expression.

RhoA is indirectly activated by PMT. The PMT-induced activation of the small GTPase RhoA is functionally connected with different families of heterotrimeric G proteins. It is known that the Gα~12/13~ and Gα~q~ families are capable of activating RhoA via guanine-nucleotide exchange factors (GEFs) like p115RhoGEF and p63RhoGEF, respectively \[[@B12-toxins-02-00205],[@B13-toxins-02-00205]\]. Studies with Gα~q/11~-deficient MEF showed that PMT stimulates RhoA in a Gα~q~-independent manner \[[@B9-toxins-02-00205]\]. Overexpression of Gα~13~ in Gα~12/13~-deficient MEF together with pharmacological inhibition of Gα~q~ restored PMT-induced stimulation of RhoA \[[@B14-toxins-02-00205]\]. However, comprehensive studies with Gα~q/11~- and Gα~12/13~-deficient MEF revealed that the toxin utilizes both families, Gα~12/13~ and Gα~q~, for stimulation of the small G protein RhoA.

Beside Gα~q~ and Gα~12/13~ the toxin activates Gα~i~. This leads to inhibition of the adenylyl cyclase \[[@B15-toxins-02-00205]\]. PMT not only activates the α-subunit of heterotrimeric G proteins, but also stimulates Gβγ-pathways by release of Gβγ from G proteins. For example, PMT causes activation of phosphoinositide-3-kinase (PI3K)γ, which is a prototypical effector of Gβγ \[[@B16-toxins-02-00205]\].

The recognition of Gα~i~ as a target of PMT was one of the experimental milestones for elucidation of the molecular mechanism of PMT. Gα~i~ is much easier to study than Gα~q~ or Gα~12/13~, because recombinant expression in *E. coli* is possible. Furthermore, its GTPase function (e.g., GTP hydrolyzing activity) can be measured easily.

To analyze the molecular mechanism of PMT, the toxin and Gα~i2~ were recombinantly co-expressed in *E. coli*. Studying Gα~i2~ from co-expression with active toxin showed inhibition of basal and RGS (regulator of G protein signaling)-stimulated GTPase activity. By tandem-mass spectrometry a difference in mass of one Dalton at glutamine-205 was detected, indicating a deamidation ([Figure 2](#toxins-02-00205-f002){ref-type="fig"}), which results in a glutamic acid residue \[[@B17-toxins-02-00205]\]. This glutamine residue is conserved throughout the GTPase superfamily and is essential for the hydrolysis of the γ-phosphate of GTP thereby terminating the active state of the GTPase \[[@B18-toxins-02-00205]\]. Deamidation of the pivotal glutamine residue results in an inhibition of the GTPase activity and arrests the G protein in a permanent active state. Functional equivalent to glutamine-205 of Gα~i2~ is glutamine-209 of Gα~q~ and Gα~11~. The deamidation of Gα~q~, which results in a change of the isoelectric point, could be demonstrated by faster migration in native gel electrophoresis. In agreement to the resistance of Gα~11~ towards PMT, no toxin-catalyzed deamidation of Gα~11~ was detectable \[[@B17-toxins-02-00205]\].

![(a) PMT deamidates the essential glutamine residue of the α-subunit of heterotrimeric G proteins, resulting in a glutamic acid residue. (b) Overview of Gα~i1~ complexed with GDP/AlF~4~^-^ mimicking the transition state of the hydrolysis of the γ-phosphate of GTP. Two essential amino acid residues are highlighted: Arginine-178 in switch 1 (magenta) and glutamine-204 (corresponding to glutamine-205 in Gα~i2~) in switch 2 (yellow). Both residues are involved in coordinating the γ-phosphate (here AlF~4~^-^) and a water nucleophile (blue sphere). PMT deamidates the glutamine residue in switch 2. Therefore, hydrolysis of the γ-phosphate of GTP is not possible anymore and the G protein is arrested in the active state. This image was generated using PyMol and PDB data file 1GFI.](toxins-02-00205-g002){#toxins-02-00205-f002}

PMT activates heterotrimeric G proteins independent of any receptor interaction. A chimera of a GPCR (α~1~-adrenoceptor) with Gα~q~ as well as a deletion mutant of Gα~q~, incapable of interacting with GPCRs is stimulated by PMT \[[@B19-toxins-02-00205]\]. Accordingly, ADP-ribosylation of Gα~i~ by pertussis toxin, which uncouples the G protein from GPCRs, has no impact on subsequent PMT-induced activation. On the other hand pre-treatment of G~i~ with PMT inhibits pertussis toxin-induced ADP-ribosylation \[[@B15-toxins-02-00205]\]. This is explained by the fact that pertussis toxin modifies the inactive, heterotrimeric G~i~ complex \[[@B20-toxins-02-00205]\]. Therefore, activation and dissociation of the heterotrimeric G protein by PMT leads to insensitivity towards pertussis toxin.

3. Structure
============

PMT is a 146-kDa protein toxin, encompassing 1,285 amino acid residues \[[@B21-toxins-02-00205]\]. It belongs to a family of dermonecrotic toxins, including the cytotoxic necrotizing factors (CNF1-3) from *Escherichia coli* and *Yersinia pseudotuberculosis* (CNFy) and dermonecrotic toxin (DNT) from *Bordetella pertussis* and *B. bronchiseptica* and PMT. These toxins share significant sequence homology in their N-terminal parts. In CNFs and DNT, the N-terminus is important for receptor binding and translocation to the cytosol \[[@B22-toxins-02-00205],[@B23-toxins-02-00205]\]. Therefore, the homology between PMT and CNFs / DNT suggests a similar function of the N-terminal part and overall a similar domain structure with a receptor binding and translocation domain in the N-terminus and a catalytic domain in the C-terminus.

In line with this model, fragments of PMT that lack the receptor or proposed translocation domains have no toxic effects, when applied to culture medium or admistered to animals \[[@B24-toxins-02-00205],[@B25-toxins-02-00205]\]. However, a C-terminal fragment without receptor binding and translocation domain, consisting of amino acid 581 to 1285, has the identical effects as full-length toxin if directly introduced into mammalian cells by electroporation \[[@B23-toxins-02-00205],[@B26-toxins-02-00205]\]. Recently, this part was crystallized ([Figure 3](#toxins-02-00205-f003){ref-type="fig"}) \[[@B27-toxins-02-00205]\]. The C-terminus of PMT consists of three domains C1, C2 and C3 with a so-called Trojan horse-like overall structure. The C1 domain (residues 569-719) has structural similarities with another bacterial protein toxin, *Clostridium diffcile* toxin B. In toxin B this domain targets the toxin to the intracellular site of the plasma membrane \[[@B28-toxins-02-00205]\]. An identical function is suggested for the PMT C1 domain \[[@B27-toxins-02-00205]\]. The C2 domain (residues 720-1104) is similar to a folylpolyglutamate synthetase but its function remains unknown. Most important is the C3 domain (residues 1105-1285) harboring the catalytic activity of the toxin.

![Domain architecture of the C-terminal part of PMT. The crystal structure of the C-terminal part of PMT (amino acids 575-1285) revealed 3 domains C1, C2 and C3. The C1 domain (magenta) has similarities with a domain of *Clostridium difficile* toxin B and targets the toxin to the inner part of the plasma membrane. The function of the C2 domain (green) is unknown. The C3 domain provides a catalytic cleft (arrow) and harbors the biological activity of the toxin. This image was generated using PyMol and PDB data file 2EBF.](toxins-02-00205-g003){#toxins-02-00205-f003}

The primary amino acid sequence of the C3 domain showed no homology to any other protein but the crystal structure revealed first insights into the possible function of PMT. Crystallization of wt-PMT leads to a structure harboring a disulfide bond between cysteine-1159 and cysteine-1165. Cleavage of this disulfide bond by mutation of cysteine-1159 to serine leads to reorientation of cysteine-1165 ([Figure 3](#toxins-02-00205-f003){ref-type="fig"} and [Figure 4](#toxins-02-00205-f004){ref-type="fig"}). The re-orientated cysteine-1165, together with histidine-1205 and aspartic acid-1220, forms a topology that resembles a catalytic triad, suggesting an essential role for these residues in the activity of PMT \[[@B27-toxins-02-00205]\]. Localization of the biological activity in the very *C*-terminus was supported by the finding that the ectopical expression of the C3 domain in mammalian cells leads to identical effects as the expression of the full-length toxin \[[@B29-toxins-02-00205]\].

![(a) Structure of the C-terminal C3 domain of PMT. This domain harbors the biological activity of the toxin with the catalytic triad (highlighted in red) cysteine-1165, histidine-1205 and aspartic acid-1220. Interestingly, cysteine-1165 of the triad is normally closed by a disulfide bridge with cysteine at position 1159 (green). Here the structure of a mutant toxin (C1159S), which releases the catalytic active cysteine-1165 from the disulfide bond, is shown. (b) Catalytic triads of thiol proteases (papain), transglutaminases (Factor XIII) and deamidases (PMT, CNF1). Catalytic active histidines were superimposed. This image was generated using PyMol and PDB data file 2EBF (PMT), 1HQ0 (CNF1), 1POP (papain) and 1GGT (Factor XIII).](toxins-02-00205-g004){#toxins-02-00205-f004}

As already described, PMT acts as a deamidase to constitutively activate heterotrimeric G proteins. The same mechanism is utilized by CNFs, which deamidate the essential glutamine in low molecular mass GTPases as RhoA, Rac or Cdc42 \[[@B30-toxins-02-00205],[@B31-toxins-02-00205]\]. In addition, DNT deamidates Rho proteins at glutamine-61(63) like CNF. Moreover, DNT can act as a transglutaminase on Rho proteins \[[@B32-toxins-02-00205],[@B33-toxins-02-00205]\]. PMT has sequence similarity with CNF and DNT in the N-terminal binding and translocation domains. In contrast, PMT has no obvious structural similarity with CNFs or DNT at the C-terminal catalytic domain \[[@B27-toxins-02-00205],[@B34-toxins-02-00205]\]. Even the topology of the catalytic center is different ([Figure 4](#toxins-02-00205-f004){ref-type="fig"}B). PMT and CNF share the catalytic amino acid residues histidine and cysteine. The third catalytic amino acid residues in the case of PMT is aspartic acid and in the case of CNF valine.

However, the catalytic triads of PMT and papain match perfectly, therefore it was suggested that PMT acts as a cysteine protease. Functional and structural comparison of deamidases and thiol proteases with transglutaminases explains this divergence. From the type of chemical reaction that they catalyze, transglutaminases, which replace the NH~2~‑group of the amide of a glutamine by another amine residue, are closely related to deamidases, which change the amide to a carboxylate by using H~2~0 as co-substrate. Furthermore, thiol proteases like papain catalyze the reverse reaction of transglutaminases. Due to this reason, it is not surprising that the catalytic triad of PMT matches the catalytic triads of thiol proteases or transglutaminases \[[@B35-toxins-02-00205],[@B36-toxins-02-00205]\]. For example, the catalytic triad (Cys-His-Asp) of the transglutaminases factor XIII perfectly matches the position of the catalytic triad of PMT.

4. Toxin Uptake
===============

To date, our knowledge about the cellular up-take of PMT is rather limited. It is generally accepted that receptor-mediated endocytosis is essential for PMT uptake by mammalian cells. Uptake could be competed with mixed gangliosides, therefore the receptor was suggested to belong to this class \[[@B37-toxins-02-00205]\]. Release of the toxin into the cytosol from early endosome is driven by acidification; consequently bafilomycin A1, an inhibitor of the vacuolar ATPases, inhibits intoxication \[[@B38-toxins-02-00205]\]. Accordingly, mimicking endosomal acidification by exposing toxin-bound cells to acidic medium leads to direct translocation of PMT to the cytosol. It is suggested that acidification induces conformational changes of PMT allowing exposure of two hydrophobic helices. The actual uptake model suggests that these helices are introduced into the endosomal membrane \[[@B39-toxins-02-00205]\]. The precise mechanism of the translocation of PMT into the cytosol remains to be elucidated.

5. Conclusions
==============

For a long time the mechanism of PMT-mediated activation of heterotrimeric G-proteins remained enigmatic. The elucidation of the crystal structure of the toxin and recognition of Gα~i~ as an additional toxin substrate were pivotal to clarify the molecular mechanism of PMT. The toxin deamidates a glutamine of the α-subunits of heterotrimeric G-proteins. This glutamine is essential for hydrolyzing GTP. Therefore, the deamidation leads to a permanent active G protein. PMT acts on different families of heterotrimeric G-proteins (Gα~i~, Gα~q~ and Gα~12/13~), even though it surprisingly distinguishes between the closely related Gα~q~ and Gα~11~. In addition to Gα-signaling, PMT induces signaling by Gβγ subunits, which are released upon activation of heterotrimeric G proteins.

Interestingly, PMT is one of the strongest mitogens known. In addition, it is known that frequent somatic mutations in the gene *Gnaq*, encoding Gα~q~, are found in melanoma of the uvea (46%) and in blue naevi (83%). These mutations result in change of glutamine-209 in a manner similar to the constitutive activation, which is caused by PMT \[[@B40-toxins-02-00205]\]. Therefore, it remains to be clarified whether the toxin plays a role in cancer development.
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